PUBLISHER: Greystone Research Associates | PRODUCT CODE: 1872364
PUBLISHER: Greystone Research Associates | PRODUCT CODE: 1872364
Self-administered On-Body Subcutaneous Infusion is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this evolving segment of the healthcare sector. The study is designed to provide drug company decision makers, drug delivery developers, device designers, healthcare marketers, and supply chain participants with a detailed understanding of the economics, technologies, disease segments, and commercial opportunities for devices that can self-administer injectable/infusible drugs subcutaneously at the point-of-care. Provider organization business managers, healthcare administrators and investors will also benefit from this study.
As prefilled devices continue to replace vials in terms of doses as well as total sector revenue, pharmaceutical and biotech program managers are increasingly integrating syringe and self-injection device technology into their development plans. The result has been a migration toward multi-functional development teams and an increasing reliance on accelerated product feasibility testing.
Research methodology is based on primary research in the form of in-depth interviews with key market participants, technology developers, distributors, industry experts, and market influencers, a list that includes regulatory officials, industry trade groups, and materials standards organizations.
Primary data is evaluated and normalized against secondary sources including trade journal articles, technical literature, industry publications, company data sheets and published information, and statistical data from government agencies and trade associations.
Forecasts and projections of market demand and future market activity are derived using standard modeling and statistical techniques.